RHH 646
Alternative Names: RHH-646Latest Information Update: 23 Mar 2025
At a glance
- Originator Novartis Pharmaceuticals
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Osteoarthritis
Most Recent Events
- 24 Feb 2025 Novartis Pharmaceuticals completes a phase II trial in Osteoarthritis (In the elderly, In adults) in the US, Spain, Poland, Denmark, Argentina (PO) (NCT05816395)
- 31 May 2023 Phase-II clinical trials in Osteoarthritis (In adults, In the elderly) in USA (PO) (NCT05816395) (EudraCT2022-502821-16-00)
- 21 Apr 2023 Novartis Pharmaceuticals plans a phase II trial for Osteoarthritis (In adults, In elderly) in May 2023 (PO) (NCT05816395) (EudraCT2022-502821-16-00)